申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US10450318B2
公开(公告)日:2019-10-22
The invention generally relates to compounds of formula I which are antagonists of CXCR4. The invention includes pharmaceutically acceptable salts, compositions, methods of making the compounds of formula I, and methods of using the compounds of formula I for therapeutic indications.
本发明一般涉及作为 CXCR4 拮抗剂的式 I 化合物。本发明包括药学上可接受的盐、组合物、制造式 I 化合物的方法以及将式 I 化合物用于治疗适应症的方法。